WATERTOWN, Mass., April 13, 2026
Enanta Pharmaceuticals, Inc. has announced the first participant dosing in its Phase 1 clinical trial of EDP-978, a novel oral, once-daily KIT inhibitor being developed for the treatment of chronic urticaria and mast cell-driven diseases. This milestone marks a critical step forward in Enanta’s immunology pipeline, targeting a condition with significant unmet medical need and limited effective therapies. The randomized, placebo-controlled study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in approximately 98 healthy volunteers, with topline data expected in Q4 2026.
Advancing First-in-Class Oral KIT Inhibitor Strategy
EDP-978 represents a highly selective and potent KIT inhibitor, designed to target mast cell activity, a central driver in chronic urticaria pathophysiology. Preclinical studies have demonstrated nanomolar potency and strong selectivity, along with favorable ADME properties, positioning it as a promising oral alternative to injectable biologics currently used in treatment-resistant patients. The initiation of Phase 1 clinical testing underscores Enanta’s strategy to develop differentiated small molecule therapies that can deliver convenience, efficacy, and scalability. By focusing on once-daily oral dosing, the company aims to improve patient adherence and long-term disease management outcomes, which remain challenging with existing therapies
Addressing High Unmet Need in Chronic Urticaria
Chronic urticaria is a debilitating inflammatory skin disorder characterized by recurrent hives, angioedema, and severe itching, often persisting for months or years. Patients frequently experience sleep disturbances, fatigue, anxiety, and reduced productivity, significantly impacting quality of life. Importantly, a substantial proportion of patients remain refractory to current standard-of-care treatments, highlighting the urgent need for new, targeted therapies. EDP-978’s mechanism of action directly inhibits KIT signaling, which plays a key role in mast cell activation and histamine release, offering the potential for more effective symptom control and disease modification. The ongoing Phase 1 trial will also assess biomarkers such as serum tryptase, providing early insights into the drug’s biological activity and therapeutic potential.
Advertisement
Clinical Development Pathway and Market Potential
The Phase 1 trial is structured to include both single-ascending dose (SAD) and multiple-ascending dose (MAD) cohorts, along with a food-effect evaluation, ensuring comprehensive assessment of EDP-978’s clinical profile. If successful, the program is expected to progress into later-stage clinical trials targeting chronic spontaneous urticaria (CSU) and other mast cell-mediated conditions, expanding its potential market reach. Enanta’s broader pipeline, which includes immunology and virology programs, reflects its commitment to addressing complex diseases through targeted molecular innovation.
With chronic urticaria affecting a significant global population and existing therapies often falling short, EDP-978 has the potential to emerge as a best-in-class oral treatment option, offering improved convenience and clinical outcomes. As Enanta advances this program, the company is positioned to capture a meaningful share of the growing immunology therapeutics market, while delivering impactful solutions for patients suffering from chronic inflammatory diseases.
Source: Enanta Pharmaceuticals press release
